A Phase 1 interventional study of Lanabecestat and Warfarin in Healthy, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-04.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 15 mg warfarin on Day 1.
Drug: Warfarin
Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
Drug: Lanabecestat · Drug: Warfarin
Administered orally
Also known as: LY3314814, AZD3293
Administered orally
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Pharmacokinetics (PK): Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound R-Warfarin
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Pharmacokinetics (PK): Area Under The Concentration Curve 0-∞(AUC) of Unbound R-Warfarin
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96,120, and 144 hours after administration of warfarin on Days 1 and 22
Pharmacodynamics (PD): Area Under the International Normalized Ratio (INR) Versus Time Curve (AUCINR) of Warfarin
Time frame: Predose, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Pharmacodynamics (PD): Maximum Observed INR Response (INRmax) of Warfarin
Time frame: Predose, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
| Milestone | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Started | 15 | 0 |
| Received at least one dose of study drug | 15 | 0 |
| Completed | 15 | 0 |
| Not completed | 0 | 0 |
| Milestone | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Started | 0 | 15 |
| Completed | 0 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| nanogram per milliliter (ng/mL) | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin | 3.50 ± 12 | 3.73 ± 14 |
| nanogram * hour per milliliter(ng*h/mL) | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin | 108 ± 18 | 123 ± 19 |
| ng/mL | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound R-Warfarin | 4.45 ± 11 | 4.80 ± 14 |
| ng*h/mL | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Pharmacokinetics (PK): Area Under The Concentration Curve 0-∞(AUC) of Unbound R-Warfarin | 262 ± 18 | 296 ± 18 |
| ng*h/mL | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Pharmacodynamics (PD): Area Under the International Normalized Ratio (INR) Versus Time Curve (AUCINR) of Warfarin | 160 ± 9 | 158 ± 6 |
| ng/mL | Warfarin | LY3314814 + Warfarin |
|---|---|---|
| Pharmacodynamics (PD): Maximum Observed INR Response (INRmax) of Warfarin | 1.29 ± 18 | 1.26 ± 12 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Warfarin | — | 0/15 (0%) | 1/15 (6.7%) |
| LY3314814 | — | 0/15 (0%) | 1/15 (6.7%) |
| LY3314814 + Warfarin | — | 0/15 (0%) | 1/15 (6.7%) |
| Event | Warfarin | LY3314814 | LY3314814 + Warfarin |
|---|---|---|---|
| Retinal haemorrhageEye disorders | 0/15 | 0/15 | 1/15 |
| Abdominal pain upperGastrointestinal disorders | 1/15 | 0/15 | 0/15 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/15 | 1/15 | 0/15 |
Participants who received one dose of study drug.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 42.9 ± 10.3 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 0 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 9 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| United States | 15 |
Ran from Sep 2015 to primary completion in Jan 2016, 4 months.
Results were first posted in Mar 2019, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lanabecestat · Warfarin